

05/14/01
31049 U.S. PTO

05-16-01

A

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity) <i>Only for new nonprovisional applications under 37 C.F.R. 1.53(b)</i>	Docket No.: 2519-A
	Express Mail Label No.: EL591094794US

JC971 U.S. PTO
09/855564
05/14/01

TO THE ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

METHODS OF USE OF THE TACI/TACI-L INTERACTION

and invented by:

GOODWIN, Raymond G. and, DIN, Wanwan S.

If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No.: 09/302,863, filed April 30, 1999

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification including claims and abstract (21 pages total)
3. ☒ Drawing(s); Number of Sheets 11
4. ☒ Oath or Declaration
 - a. ☐ Newly executed
 - b. ☒ Copy from a prior application (37.C.F.R. 1.63(d)) (*for continuation/divisional application only*)
 - c. ☒ With Power of Attorney ☐ Without Power of Attorney
 - d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation by Reference (usable if Box 4b is checked)
The entire disclosure of the prior application from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
 - a. ☒ Paper copy
 - ☐ Pages _____ - _____ of specification
 - ☒ Separately numbered pages 1 - 7
 - b. ☐ Computer Readable Copy
 - c. ☐ Statement Verifying Identical Paper and Computer Readable Copy
 - d. ☒ Statement under 37 C.F.R. 1.821(e) in lieu of Computer Readable Copy

09/855564

Accompanying Application Parts

8. ☒ Assignment
- a. ☐ Executed original Assignment and Recordation Form enclosed
- b. ☒ Prior application is assigned of record to Immunex Corporation
(reel 010170 frame 0554)
9. ☐ 37 C.F.R. 3.73(B) Statement (*when there is an assignee*)
10. ☒ Preliminary Amendment
11. ☒ Acknowledgment postcard
12. ☒ Certificate of Mailing by Express Mail (Label No.: EL591094794US)
13. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
14. ☒ Additional Enclosures (*please identify below*):


Information Disclosure Statement; Form PTO-1449; Cited Reference (1)

Fee Calculation and Transmittal

CLAIMS AS FILED (after any Preliminary Amendment submitted herewith)					
For	# Filed	# Allowed	# Extra	Rate	Fee
Total Claims	4	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$80.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$710.00
OTHER FEE (<i>specify purpose</i>)					\$0.00
TOTAL FILING FEE					\$710.00

- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 09-0089 as described below. A copy of this sheet is enclosed.
- ☒ Charge the amount of \$710.00 as a filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional fees required under 37 C.F.R. 1.16 and 1.17.

Correspondence address:


 Simone L. Jones
 Registration No. 41,951

Dated: May 14, 2001



22932

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Raymond G. Goodwin and Wanwan S. Din Docket No. 2519-A
Serial No.: --to be assigned-- Art Unit: Unknown
Filing Date: May 14, 2001 Examiner: Unknown
For: METHODS OF USE OF THE TACI/TACI-L INTERACTION

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examining this continuation application, please enter the following amendment.

In the Specification:

Before page 1, line 7, please add:

This application is a continuation of U.S. application Serial No. 09/302,863, filed April 30, 1999, pending.

In the Claims:

Please delete claims 1-14 and add new claims 15-18.


15. (new) A purified nucleic acid comprising extracellular TACI and a Fc fragment.

16. (new) The nucleic acid of claim 1, wherein the Fc fragment is human IgG1.

17. (new) The nucleic acid of claim 1, wherein the extracellular TACI is the nucleotide sequence encoding the amino acids 2-166 of SEQ ID NO:2.

18. (new) A TACI:Fc protein comprising amino acids selected from the group consisting of (a) amino acids 2-166 of SEQ ID NO:2; (b) amino acids at least 75% identical to amino acids 2-166 of SEQ ID NO:2 and (c) fragments of amino acids 2-166; wherein (a), (b) and (c) retain the biological ability to bind to TACI-L.

Respectfully submitted,


Simone L. Jones
Registration No. 41,951

Law Department
Immunex Corporation
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Raymond G. Goodwin and Wanwan S. Din
Serial No.: --to be assigned--
Filing Date: May 14, 2001
For: METHODS OF USE OF THE TACI/TACI-L INTERACTION

Docket No. 2519-A
Art Unit: Unknown
Examiner: Unknown



STATEMENT UNDER 37 CFR 1.821(e)

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


Applicants by their undersigned agent hereby state that no computer readable form of the Sequence Listing is necessary for this application because it would be identical to the computer readable form submitted for the following patent application:

Applicants: Raymond G. Goodwin and Wanwan S. Din
Serial No.: 09/302,863
Filed: April 30, 1999
Title: METHODS OF USE OF THE TACI/TACI-L INTERACTION

In accordance with 37 C.F.R. § 1.821(e), please use the only computer readable form filed in that application on August 9, 1999, as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included for the instant application. No new matter has been added.

Thus, Applicants request the use of the above-identified compliant sequence listing in the instant application.

Respectfully submitted,


Simone L. Jones
Registration No. 41,951

Law Department
Immunex Corporation
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Raymond G. Goodwin and Wanwan S. Din Docket No. 2519-A
Serial No.: --to be assigned-- Art Unit: Unknown
Filing Date: May 14, 2001 Examiner: Unknown
For: METHODS OF USE OF THE TACI/TACI-L INTERACTION

CERTIFICATE OF MAILING BY EXPRESS MAIL

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

EXPRESS MAIL LABEL NUMBER: EL591094894US

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date listed below, and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Utility Patent Application Cover Letter (+ copy)
Specification, Claims and Abstract (21 pages)
Preliminary Amendment
Paper Copy of Sequence Listing (7 pages)
Statement Under 37 CFR §1.821(e)
Figures (6), Sheets (11)
Information Disclosure Statement
Form PTO-1449
Copy of Cited Reference (1)
Postcard

Signed: Nanci M. Kertson
Nanci M. Kertson

Date: May 14, 2001